These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 34614550)

  • 1. Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign.
    Ferrari D; Mangia A; Spanò MS; Zaffarano L; Viganò M; Di Resta C; Locatelli M; Ciceri F; De Vecchi E
    Clin Chem Lab Med; 2021 Nov; 59(12):2019-2026. PubMed ID: 34614550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.
    Callegaro A; Borleri D; Farina C; Napolitano G; Valenti D; Rizzi M; Maggiolo F
    J Med Virol; 2021 Jul; 93(7):4612-4615. PubMed ID: 33788281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects.
    Ferrari D; Di Resta C; Tomaiuolo R; Sabetta E; Pontillo M; Motta A; Locatelli M
    Vaccine; 2021 Jul; 39(31):4256-4260. PubMed ID: 34147292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals.
    Fraley E; LeMaster C; Geanes E; Banerjee D; Khanal S; Grundberg E; Selvarangan R; Bradley T
    BMC Med; 2021 Jul; 19(1):169. PubMed ID: 34304742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
    Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
    Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological response in health care workers after a single dose of SARS-CoV-2 vaccine using six automated SARS-CoV-2 antibody assays.
    Cuykx M; Mortelé O; Jansens H; Schouwers S; Meskal A; Hoffbauer I; Peeters B
    Diagn Microbiol Infect Dis; 2021 Oct; 101(2):115486. PubMed ID: 34332306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).
    Favresse J; Bayart JL; Mullier F; Dogné JM; Closset M; Douxfils J
    Clin Microbiol Infect; 2021 Sep; 27(9):1351.e5-1351.e7. PubMed ID: 33975007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19.
    Mazzoni A; Di Lauria N; Maggi L; Salvati L; Vanni A; Capone M; Lamacchia G; Mantengoli E; Spinicci M; Zammarchi L; Kiros ST; Rocca A; Lagi F; Colao MG; Parronchi P; Scaletti C; Turco L; Liotta F; Rossolini GM; Cosmi L; Bartoloni A; Annunziato F;
    J Clin Invest; 2021 Jun; 131(12):. PubMed ID: 33939647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.
    Chan RWY; Liu S; Cheung JY; Tsun JGS; Chan KC; Chan KYY; Fung GPG; Li AM; Lam HS
    Front Immunol; 2021; 12():744887. PubMed ID: 34712232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.
    Rastawicki W; Płaza K
    Przegl Epidemiol; 2021; 75(1):3-13. PubMed ID: 34328282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics and biological characteristics of humoral response developing after SARS-CoV-2 infection: implications for vaccination.
    Lippi G; Sciacovelli L; Trenti T; Plebani M;
    Clin Chem Lab Med; 2021 Jul; 59(8):1333-1335. PubMed ID: 33578505
    [No Abstract]   [Full Text] [Related]  

  • 15. Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine.
    Meschi S; Matusali G; Colavita F; Lapa D; Bordi L; Puro V; Leoni BD; Galli C; Capobianchi MR; Castilletti C;
    Clin Chem Lab Med; 2021 Nov; 59(12):2010-2018. PubMed ID: 34492749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response.
    Ontañón J; Blas J; de Cabo C; Santos C; Ruiz-Escribano E; García A; Marín L; Sáez L; Beato JL; Rada R; Navarro L; Sainz de Baranda C; Solera J
    EBioMedicine; 2021 Nov; 73():103656. PubMed ID: 34740112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
    Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
    EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations.
    Efrati S; Catalogna M; Abu Hamad R; Hadanny A; Bar-Chaim A; Benveniste-Levkovitz P; Levtzion-Korach O
    Sci Rep; 2021 Aug; 11(1):16543. PubMed ID: 34400714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals.
    Hirotsu Y; Amemiya K; Sugiura H; Shinohara M; Takatori M; Mochizuki H; Omata M
    Front Immunol; 2021; 12():722766. PubMed ID: 34512649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.